Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Harvard Business School
Boehringer Ingelheim
QuintilesIMS
Fish and Richardson
Merck
Cipla
UBS
McKesson

Generated: July 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,198,801

« Back to Dashboard

Summary for Patent: 7,198,801
Title:Formulations for transdermal or transmucosal application
Abstract:The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
Inventor(s): Carrara; Dario Norberto R. (Oberwil, CH), Grenier; Arnaud (Steinbrunn le Haut, FR), Besse; Celine (Saint Louis, FR), Simes; Stephen M. (Long Grove, IL), Lehman; Leah M. (Green Oaks, IL)
Assignee: Antares Pharma IPL AG (Zug, CH)
Application Number:10/798,161
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,198,801
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery;

Drugs Protected by US Patent 7,198,801

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan Speciality Lp ELESTRIN estradiol GEL, METERED;TRANSDERMAL 021813-001 Dec 15, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Allergan Sales Llc GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,198,801

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/EP00/07533Aug 03, 2000

Non-Orange Book US Patents Family Members for Patent 7,198,801

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,470,433 Formulations for transdermal or transmucosal application ➤ Try a Free Trial
8,652,491 Transdermal compositions for anticholinergic agents ➤ Try a Free Trial
7,214,381 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels ➤ Try a Free Trial
8,980,290 Transdermal compositions for anticholinergic agents ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,198,801

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 030312 ➤ Try a Free Trial
Austria 355854 ➤ Try a Free Trial
Austria 356636 ➤ Try a Free Trial
Austria 485837 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Colorcon
Healthtrust
Farmers Insurance
Citi
Deloitte
US Department of Justice
Express Scripts
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.